Non-alcoholic fatty liver disease surgery

Jump to navigation Jump to search

Non-Alcoholic Fatty Liver Disease Microchapters


Patient Information


Historical Perspective




Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


X Ray




Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Non-alcoholic fatty liver disease surgery

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease surgery

CDC on Non-alcoholic fatty liver disease surgery

Non-alcoholic fatty liver disease surgery in the news

Blogs on Non-alcoholic fatty liver disease surgery

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]


Surgery is not the first-line treatment option for patients with non- Alcoholic fatty liver disease (NAFLD). However, gastric bypass surgery is recommended in patients with non-alcoholic fatty liver disease whose BMI is greater than 40 who psychologically stable and failed medical therapy.



  • Patients with NAFLD and BMI greater than 40 who psychologically stable
  • In patients who failed medical therapy.

Surgical options

  • The size of the stomach is reduced either by stapling or banding, creating a small pouch, assisting with weight loss by inducing
  • The feasibility of liver transplantation depends on the stage of NAFLD at diagnosis.NAFLD is emerging as the second most common cause for liver transplant.[4][5]
    • Indication 1 End stage liver-disease 
    • Indication 2 Hepatocellular carcinoma (HCC) are the two most important indications for the liver transplant.
    • Outcome : After liver transplanation patients with or without NASH may survive 1,3 and 5 years and are increasinly at risk for cardio vascular risks.[6]



  1. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  2. Boscolo M, Féry F, Cnop M (2017). "Beneficial Outcomes of Sleeve Gastrectomy in a Morbidly Obese Patient With Bardet-Biedl Syndrome". J Endocr Soc. 1 (4): 317–322. doi:10.1210/js.2017-00071. PMID 29264490.
  3. Colquitt JL, Pickett K, Loveman E, Frampton GK (2014). "Surgery for weight loss in adults". Cochrane Database Syst Rev (8): CD003641. doi:10.1002/14651858.CD003641.pub4. PMID 25105982.
  4. Germani G, Becchetti C (2017). "Liver transplantation for non-alcoholic fatty liver disease". Minerva Gastroenterol Dietol. doi:10.23736/S1121-421X.17.02467-9. PMID 29249127.
  5. Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A (2017). "Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes". Dig. Dis. Sci. 62 (10): 2915–2922. doi:10.1007/s10620-017-4684-x. PMID 28744836.
  6. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y (2014). "Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis". Clin. Gastroenterol. Hepatol. 12 (3): 394–402.e1. doi:10.1016/j.cgh.2013.09.023. PMID 24076414.

Template:WS Template:WH